Therapeutic Candidate or Device TriLeukeVax, an autologous AML vaccine designed to stimulate induction of anti-leukemic cytolytic activity and improve relapse free survival (RFS). Indication Older leukemia patients who achieve remission…
Therapeutic Candidate or Device CLT030-ADC, a novel drug targeting a leukemic stem cell surface protein CLL1, is intended to improve therapeutic outcome for AML patients. Indication CLT030-ADC is intended to…
Dr. Matthew H Porteus and his team at Stanford will test an immunotherapy cell approach using a therapy that is enriched with specialized immune cells called type I regulatory T…
Immune-Onc Therapeutics will conduct a clinical trial for patients with acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML), both of which are types of blood cancer. AML affects approximately 20,000…
Forty Seven Inc. is conducting a Phase 1b clinical trial for acute myeloid leukemia patients. Leukemia stem cells have a protein on their surface that enable them to evade being…
Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after…
Research Objective This study will address gaps in our understanding of how normal and cancer stem cells differ in their epigenetic states, helping develop new cancer-stem-cell-targeting therapis. Impact The long-term…
Research Objective Genetically modified cells that help control immune reactions Impact Improved treatment for patients undergoing transplantation Major Proposed Activities To identify the optimal source of regulatory T cells for…
Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
